FY2022 Q2 Financial Results Presentation

On October 31, 2022 Daiichi Sankyo reported its second quarter financial results (Presentation, Daiichi Sankyo, OCT 31, 2022, View Source [SID1234624534]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2022 [IFRS]

On October 31, 2022 Otsuka reported its consolidated Financial results for the Third Quarter of the fiscal year ending December 31, 2022 (Press release, Otsuka, OCT 31, 2022, View Source [SID1234624422]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2023

On October 31, 2022 Ono reported that its Financial Results for the Second Quarter of the fiscal year ending March 31, 2023 (Filing, 3 mnth, SEP 30, Ono, 2022, OCT 31, 2022, View Source [SID1234624418]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022

On October 31, 2022 Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, reported that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Company’s business operations and clinical development programs on November 8, 2022, before the U.S. financial markets open (Press release, Reata Pharmaceuticals, OCT 31, 2022, View Sourcenews/news-details/2022/Reata-Pharmaceuticals-Inc.-to-Report-Third-Quarter-2022-Financial-Results-and-to-Provide-an-Update-on-Clinical-Development-Programs-on-November-8-2022/default.aspx" target="_blank" title="View Sourcenews/news-details/2022/Reata-Pharmaceuticals-Inc.-to-Report-Third-Quarter-2022-Financial-Results-and-to-Provide-an-Update-on-Clinical-Development-Programs-on-November-8-2022/default.aspx" rel="nofollow">View Source [SID1234622727]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

Reata’s management will host a conference call on November 8, 2022, at 8:30 am ET. The conference call will be accessible by dialing (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) using access code 756839. The webcast link is View Source

Third quarter 2022 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at View Source and will be available for 12 months after the call. The audio recording and webcast of the conference call will be accessible for at least 90 days after the event at View Source.

Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022

On October 31, 2022 Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) reported that it will host a conference call and live webcast on Tuesday, November 1, 2022, at 8:30 a.m. Eastern Time to report its third quarter 2022 financial results and corporate activities (Press release, Kiniksa Pharmaceuticals, OCT 31, 2022, View Source [SID1234622725]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.